Nemkova S A, Semenov D V, Zavadenko N N, Vozvyshaeva M Yu
Pirogov Russian National Research Medical University, Moscow, Russia.
Zh Nevrol Psikhiatr Im S S Korsakova. 2021;121(1):43-46. doi: 10.17116/jnevro202112101143.
The aim of the study was to study the effect of the drug recognan (citicoline) on the neurodynamic characteristics of mental activity in patients with mild cognitive impairment.
A survey of 58 subjects (17 of them male and 41 female) aged 18-45 years (average age 27.2±12.5 years) was conducted. Clinical diagnosis according to ICD-10 «Mild cognitive impairment» (F06.7). The main subgroup included29 people received oral recognan therapy (in solution, 100 mg in 1 ml) for 30 days, with a daily dosage of 500 mg (5 ml of solution). In the control group (29 people) drug therapy was not performed. Tests were used: «Graphic sample», the sample on the reciprocal coordination of the hands (Ozeretsky test), test for the compression of fingers, the test «number series». The follow-up period was 30 days. All subjects were examined three times (initially, in the middle of the study - on day 15, at the end of the study - on day 30).
The results obtained showed that the use of the drug recognan (citicoline) has a positive effect on the indicators of visual-motor coordination and spatial representations, neurodynamic characteristics of movement, and cognitive functions. After a 2-week treatment with recognan improved graphical sample, 84% of patients, with reliable improvement according to the Wilcoxon (=0.0002), the sample in the compression of the fingers 60%, as well as coordination 60%, the accounting functions in 44%. After a month (30 day) treatment course recomanem there was an increase in indices of samples for the compression of fingers in 71.4% of patients, with significant improvement (=0.0499) and run the graphical samples of 71.4%, coordination at 46.4%, counting functions - 48% patients.
本研究旨在探讨药物瑞可南（胞磷胆碱）对轻度认知障碍患者精神活动神经动力学特征的影响。
对58名年龄在18 - 45岁（平均年龄27.2±12.5岁）的受试者（其中男性17名，女性41名）进行了调查。根据ICD - 10标准进行“轻度认知障碍”（F06.7）的临床诊断。主要亚组包括29人接受口服瑞可南治疗（溶液剂，1ml含100mg），疗程30天，每日剂量500mg（5ml溶液）。对照组（29人）未进行药物治疗。使用的测试包括：“图形样本”、双手交互协调样本（奥泽列茨基测试）、手指挤压测试、“数字序列”测试。随访期为30天。所有受试者进行了三次检查（初始、研究中期 - 第15天、研究结束 - 第30天）。
所得结果表明，使用药物瑞可南（胞磷胆碱）对视觉 - 运动协调指标、空间表象、运动神经动力学特征及认知功能有积极影响。瑞可南治疗2周后，84%的患者图形样本改善，根据威尔科克森检验有可靠改善（=0.0002），手指挤压样本改善60%，协调性改善60%，计数功能改善44%。经过一个月（30天）的瑞可南治疗疗程后，71.4%的患者手指挤压样本指标增加，有显著改善（=0.0499），图形样本运行改善71.4%，协调性改善46.4%，计数功能 - 48%的患者改善。
